One-year outcome following biological or mechanical valve replacement for infective endocarditis
Language English Country Netherlands Media print-electronic
Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't
PubMed
25464234
DOI
10.1016/j.ijcard.2014.10.125
PII: S0167-5273(14)02062-2
Knihovny.cz E-resources
- Keywords
- Infective endocarditis, Surgery, Valve prosthesis,
- MeSH
- Bioprosthesis microbiology trends MeSH
- Heart Valve Prosthesis Implantation mortality trends MeSH
- Endocarditis diagnosis mortality surgery MeSH
- Prosthesis-Related Infections diagnosis mortality MeSH
- Cohort Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Mortality trends MeSH
- Prospective Studies MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. METHODS AND RESULTS: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p=0.0009) and 25.3% vs 16.6% (p<.0001), respectively. In multivariable analysis, mechanical prostheses were less commonly implanted in older patients (odds ratio: 0.64 for every 10years), and in patients with a history of cancer (0.72), but were more commonly implanted in mitral position (1.60). Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298). CONCLUSIONS: Patients with IE who receive a biological valve replacement have significant differences in clinical characteristics compared to patients who receive a mechanical prosthesis. Biological valve replacement is independently associated with a higher in-hospital and 1-year mortality, a result which is possibly related to patient characteristics rather than valve dysfunction.
American University of Beirut Medical Center Beirut Lebanon
Canberra Hospital Woden Australia
CHU Nancy Brabois Nancy France
Duke University Medical Center Durham NC USA
Flinders Medical Centre Adelaide Australia
Hopital Louis Pradel Lyon Bron France
Hospital Clinic IDIBAPS Barcelona Spain
Instituto Nacional de Cardiologia Rio de Janerio Brazil
Khon Kaen University Khon Kaen Thailand
Mater Hospitals Dublin Ireland
Medical Center Ljubljana Slovenia
Pontchaillou University Hospital Rennes France
Sanatorio de la Trinidad Mitre Buenos Aires Argentina
References provided by Crossref.org